TIGIT

TIGIT
Available structures
PDB	Ortholog search: PDBe RCSB
List of PDB id codes
	3Q0H, 3RQ3, 3UCR, 3UDW
Identifiers
Aliases	TIGIT, VSIG9, VSTM3, WUCAM, T-cell immunoreceptor with Ig and ITIM domains, T cell immunoreceptor with Ig and ITIM domains
External IDs	OMIM: 612859; MGI: 3642260; HomoloGene: 18358; GeneCards: TIGIT; OMA:TIGIT - orthologs
Gene location (Human)
Chr.	Chromosome 3 (human)
End	114,310,288 bp
Gene location (Mouse)
Chr.	Chromosome 16 (mouse)
End	43,484,509 bp
RNA expression pattern
	Top expressed in
	granulocyte; ; lymph node; ; gonad; ; appendix; ; testicle; ; spleen; ; oocyte; ; secondary oocyte; ; blood; ; gallbladder;
	Top expressed in
	jejunum; ; ileum; ; spleen; ; blastocyst; ; morula; ; thymus; ; colon; ; secondary oocyte; ; duodenum; ; placenta;
	More reference expression data
	n/a
Gene ontology
Molecular function	signaling receptor binding; protein binding; protein homodimerization activity; cell adhesion molecule binding; identical protein binding;
Cellular component	integral component of membrane; cell surface; plasma membrane; integral component of plasma membrane; membrane;
Biological process	heterophilic cell-cell adhesion via plasma membrane cell adhesion molecules; cell recognition; negative regulation of T cell activation; positive regulation of interleukin-10 production; homophilic cell adhesion via plasma membrane adhesion molecules; negative regulation of interleukin-12 production;
	Sources:Amigo / QuickGO
Orthologs
	201633
	100043314
	ENSG00000181847
	ENSMUSG00000071552
	Q495A1
	P86176
	NM_173799
	NM_001146325
	NP_776160
	NP_001139797
	Wikidata
View/Edit Human	View/Edit Mouse

TIGIT (/ˈtɪdʒɪt/ TIJ-it; also called T cell immunoreceptor with Ig and ITIM domains) is an immune receptor present on some T cells and natural killer cells (NK). It is also identified as WUCAM and Vstm3. TIGIT could bind to CD155 (PVR) on dendritic cells (DCs), macrophages, etc. with high affinity, and also to CD112 (PVRL2) with lower affinity.

Numerous clinical trials on TIGIT-blockade in cancer have recently been initiated, predominantly combination treatments. The first interim results show promise for combined TIGIT and PD-L1 co-blockade in solid cancer patients. Mechanistically, research has shown that TIGIT-Fc fusion protein could interact with PVR on dendritic cells and increase its IL-10 secretion level/decrease its IL-12 secretion level under LPS stimulation, and also inhibit T cell activation in vivo. TIGIT's inhibition of NK cytotoxicity can be blocked by antibodies against its interaction with PVR and the activity is directed through its ITIM domain.